NovoTTF-200T

DEVICE5 trials

Conditions

Metastatic Non-small Cell Lung CancerNSCLCNon-Small Cell Lung Cancer (NSCLC)Non-small Cell Lung CancerNonsmall Cell Lung CancerPancreas Adenocarcinoma

Phase 2

EF-36/Keynote B36: A Pilot, Randomized, Open-label Study of Tumor Treating Fields (TTFields, 150 kHz) Concomitant With Pembrolizumab for First Line Treatment of Advanced or Metastatic Non-small Cell Lung Cancer

TerminatedNCT04892472

NovoCure GmbHNon-small Cell Lung Cancer

Start: 2021-07-12End: 2025-01-10Updated: 2025-04-23

LUNAR-4: Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Pembrolizumab for Treatment of Metastatic Non-small Cell Lung Cancer (NSCLC)

Active, not recruitingNCT06558799

NovoCure GmbHNon-Small Cell Lung Cancer (NSCLC)

Start: 2024-10-14End: 2026-01-31Target: 69Updated: 2025-10-28

Phase 3

Effect of Tumor Treating Fields (TTFields) (150 kHz) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure (LUNAR)

CompletedNCT02973789

NovoCure GmbHNonsmall Cell Lung Cancer, NSCLC

Start: 2016-12-01End: 2024-10-09Updated: 2026-03-18

Effect of Tumor Treating Fields (TTFields, 150 kHz) as Front-Line Treatment of Locally-advanced Pancreatic Adenocarcinoma Concomitant With Gemcitabine and Nab-paclitaxel (PANOVA-3)

CompletedNCT03377491

NovoCure Ltd.Pancreas Adenocarcinoma

Start: 2018-05-10End: 2024-10-16Updated: 2026-01-21

LUNAR-2: TTFields With Pembrolizumab + Platinum-based Chemotherapy for Metastatic NSCLC

RecruitingNCT06216301

NovoCure GmbHMetastatic Non-small Cell Lung Cancer

Start: 2024-07-31End: 2028-10-31Target: 734Updated: 2025-12-17

Cancer Research2026-04-03

Subgroup analyses from the phase 3 PANOVA-3 trial of tumor treating fields (TTFields) with gemcitabine/nab-paclitaxel in locally advanced pancreatic adenocarcinoma: Efficacy and safety by sex, age, and body mass index (BMI).

Journal of Clinical Oncology2026-01-10

PANOVA-3: Phase 3 study of tumor treating fields (TTFields) with gemcitabine and nab-paclitaxel for locally advanced pancreatic ductal adenocarcinoma (LA-PAC).

Journal of Clinical Oncology2025-06-04

Tumor Treating Fields (TTFields) Therapy in Unresectable Pleural Mesothelioma: Overview of Efficacy, Safety, and Future Outlook.

2025-04-23

Abstract A008: The effect of body mass index on Tumor Treating Fields (TTFields) intensity distribution in the abdomen: results of a simulation model study

Cancer Research2024-09-15

LUNAR-2: Pivotal, randomized, open-label study of tumor treating fields (TTFields, 150 kHz) concomitant with pembrolizumab and platinum based chemotherapy for the treatment of metastatic non-small cell lung cancer.

Journal of Clinical Oncology2024-06-01

Pneumologische Onkologie Tumor Treating Fields (TTFields) therapy with standard systemic therapy in metastatic non-small cell lung cancer following progression on or after platinum-based therapy: global randomized, pivotal (phase 3) LUNAR study

Pneumologie2024-03-01

PANOVA-4 (EF-39): Pilot study of tumor treating fields (TTFields) therapy with atezolizumab, gemcitabine (GEM), and nab-paclitaxel (NabP) as first-line (1L) treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).

Journal of Clinical Oncology2024-01-202 citations

Tumor Treating Fields (TTFields) demonstrate antiviral functions in vitro, and safety for application to COVID-19 patients in a pilot clinical study

Frontiers in Microbiology2023-11-29

607 TTFields therapy with an immune checkpoint inhibitor in metastatic non-small cell lung cancer (mNSCLC) with progression on/after platinum-based therapy: histology subgroups in the pivotal LUNAR study

Regular and Young Investigator Award Abstracts2023-10-31

Tumor Treating Fields therapy with standard systemic therapy versus standard systemic therapy alone in metastatic non-small-cell lung cancer following progression on or after platinum-based therapy (LUNAR): a randomised, open-label, pivotal phase 3 study.

2023-09-0167 citations

Tumor Treating Field (TTFields) therapy with standard of care (SOC) in metastatic non-small cell lung cancer (mNSCLC) following platinum failure: Randomized, phase 3 LUNAR study.

Journal of Clinical Oncology2023-06-074 citations

Phase 3 PANOVA-3 study: Tumor treating fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer.

Journal of Clinical Oncology2023-06-011 citations

The association between body mass index and distribution intensity of tumor treating fields (TTFields) in the lungs.

Journal of Clinical Oncology2023-06-01

Computational Analysis of Tumor Treating Fields for Non-Small Cell Lung Cancer in Full Thoracic Models.

2023-02-266 citations

Tumor treating fields (TTFields) concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer: The phase 3 PANOVA-3 study.

Journal of Clinical Oncology2023-01-24

Abstract A021: Tumor Treating Fields (TTFields) therapy concomitant with gemcitabine and nab-paclitaxel (GnP) for front-line treatment of locally advanced pancreatic cancer: the phase 3 PANOVA-3 study

Cancer Research2022-11-15

703 First-line tumor treating fields (TTFields; 150 kHz) therapy plus pembrolizumab for advanced or metastatic intrathoracic non-small cell lung cancer: the phase 2 EF-36/KEYNOTE B36 pilot study

Regular and Young Investigator Award Abstracts2022-11-011 citations

Abstract CT234: PANOVA-3: A phase 3 study of tumor treating fields with gemcitabine and nab-paclitaxel for front-line treatment of locally advanced pancreatic adenocarcinoma

Cancer Research2022-06-15

PANOVA-3: A phase 3 study of tumor-treating fields with gemcitabine and nab-paclitaxel for frontline treatment of locally advanced pancreatic adenocarcinoma.

Journal of Clinical Oncology2022-06-011 citations

20 more papers not shown

NovoTTF-200T

Sponsors

Conditions

Phase 2

Phase 3

Related Papers